echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > How to synthesize the anti-coronavirus oral drug Molnupiravir quickly and in high yield?

    How to synthesize the anti-coronavirus oral drug Molnupiravir quickly and in high yield?

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Image Copyright: 2009-2021 Merck Sharp & Dohme Corp

    As SARS-CoV-2 continues to spread and mutate, it is important to determine new treatment options


    Molnupiravir was originally used to treat influenza.


    John McIntosh, Patrick Fier and colleagues of Merck and Codexis set out to develop a shorter, more productive, and sustainable way to synthesize this molecule


    Researchers have developed a three-step synthesis method to synthesize Molnupiravir from a sugar molecule called ribose


    The author of the research report admitted that the funding came from Merck Sharp & Dohme Corp


    10.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.